The patents significantly broaden protection for the technology--and for its use to treat a wide variety of diseases
LEXINGTON, Mass., Dec. 19, 2016 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received five patents over the last 12 months.
"These new patents are further proof that our iSPERSE™ inhaled drug technology is innovative," said Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix. "These patents give us stronger composition of matter and method of use intellectual property protection as we move forward to develop drugs for COPD, fungal infections, and other diseases."
Two of the patents (US 9,233,158 and US 9,238,005) extend existing patent coverage in the United States. Two more (JP 5,877,201 and JP 5,964,939) provide similar extensions in Japan.
The fifth patent (US 9,433,576), which was granted on September 6, 2016, broadens the patent protection for Pulmatrix's innovative drug delivery technology and its use to treat a wide variety of diseases.
As the patent explains, delivering drugs directly to the lungs offers numerous advantages. But existing technologies have serious limitations, such as leaving much of the drug stuck in the mouth or throat, causing side effects. "Therefore, there remains a need for the formation of small particle size aerosols that are highly dispersible," the patent says.
Pulmatrix's technology seeks to meet that need. Its dry powder 'flies' easily into the lungs, reducing the amount stuck in the throat. In addition, the technology can deliver much larger doses of drugs—and many more different types of drugs—than existing methods can.
The patent recognizes the advantages of the technology and grants intellectual property protection for many different medical uses of Pulmatrix's technology. As the patent states: "The invention also relates to methods for treating a respiratory disease, such as asthma, airway hyper-responsiveness, seasonal allergic allergy, bronchiectasis, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, cystic fibrosis and the like."
"As we look to continue to advance our pipeline, these patents will prevent competitors from copying our technology," added Dr. Clarke.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for lung diseases, including opportunities in major pulmonary diseases through collaborations, like PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) and PUR1900, an inhaled antifungal that could benefit severe asthmatics and patients with rare disease like cystic fibrosis. Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's annual report on Form 10-K filed by the Company with the Securities and Exchange Commission on March 10, 2016. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Robert Clarke, CEO
William Duke, CFO
SOURCE Pulmatrix, Inc.